CSL Vi­for pro­pos­es a mar­ket­ing cam­paign to set­tle Eu­ro­pean Com­mis­sion in­ves­ti­ga­tion

CSL Vi­for is look­ing to close out a Eu­ro­pean an­ti-com­pet­i­tive in­ves­ti­ga­tion with a pro­posed mar­ket­ing cam­paign.

The Eu­ro­pean Com­mis­sion be­gan in­ves­ti­gat­ing Vi­for Phar­ma, now CSL Vi­for, in June 2022 over al­le­ga­tions it il­le­gal­ly dis­par­aged its IV iron in­fu­sion com­peti­tor, Phar­ma­cos­mos’ Monofer. The EC al­leged Vi­for’s ac­tions were aimed at sti­fling com­pe­ti­tion for its own high-dose iron IV brand Fer­in­ject, which is mar­ket­ed as In­jectafer in the US.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER